Screener
Amneal Pharmaceuticals, Inc. AMRX Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:22 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001723128-26-000020
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash used in investing activities | (21,710) | (17,798) |
| Cash flows from financing activities: | ||
| Payments of principal on debt, revolving credit facilities, financing leases and other | (140,842) | (235,528) |
| Proceeds from issuance of debt | 134,673 | — |
| Payments of deferred financing and refinancing costs | (1,982) | — |
| Borrowings on revolving credit facilities | — | 218,000 |
| Proceeds from exercise of stock options | 38 | 69 |
| Employee payroll tax withholding on restricted stock unit vesting | (44,305) | (21,639) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s debt issuance proceeds?
- Amneal Pharmaceuticals, Inc. (AMRX) reported debt issuance proceeds of $134.67M in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Amneal Pharmaceuticals, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude